Burning Rock Biotech (BNR) Stock Forecast, Price & News

0 analysts have issued twelve-month price objectives for Burning Rock Biotech's stock. Their BNR share price forecasts range from $76.00 to $100.00. On average, they expect the company's stock price to reach $86.61 in the next year. This suggests a possible upside of 3,665.7% from the stock's current price.
View analysts price targets for BNR or view top-rated stocks among Wall Street analysts.

Burning Rock Biotech's stock was trading at $59.72 at the beginning of 2023. Since then, BNR shares have decreased by 96.1% and is now trading at $2.30.
View the best growth stocks for 2023 here.

Burning Rock Biotech saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 608,200 shares, a drop of 17.4% from the April 30th total of 736,000 shares. Based on an average daily trading volume, of 74,400 shares, the short-interest ratio is currently 8.2 days. Approximately 0.7% of the company's shares are short sold.
View Burning Rock Biotech's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 30th 2023.
View our BNR earnings forecast.

Burning Rock Biotech Limited (NASDAQ:BNR) released its earnings results on Tuesday, March, 28th. The company reported ($0.31) earnings per share (EPS) for the quarter. The firm had revenue of $20.62 million for the quarter, compared to analyst estimates of $15.60 million. Burning Rock Biotech had a negative trailing twelve-month return on equity of 72.57% and a negative net margin of 157.30%.

ETFs with the largest weight of Burning Rock Biotech (NASDAQ:BNR) stock in their portfolio include Loncar China Biopharma ETF (CHNA), Invesco Golden Dragon China ETF (PGJ),

Burning Rock Biotech issued an update on its FY 2023 earnings guidance on Tuesday, May, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $97.99 million-$97.99 million, compared to the consensus revenue estimate of $95.89 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Burning Rock Biotech investors own include Tiziana Life Sciences (TLSA), Teck Resources (TECK), Herman Miller (MLHR) and Immunic (IMUX).

(BNR) raised $196 million in an initial public offering on Friday, June 12th 2020. The company issued 13,500,000 shares at $13.50-$15.50 per share. Morgan Stanley, BofA Securities and Cowen served as the underwriters for the IPO and CMBI and Tiger Brokers were co-managers.

Burning Rock Biotech trades on the NASDAQ under the ticker symbol "BNR."

Burning Rock Biotech's stock is owned by many different retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.63%), Nikko Asset Management Americas Inc. (0.62%), Barclays PLC (0.58%), Renaissance Technologies LLC (0.35%), Assenagon Asset Management S.A. (0.26%) and Schonfeld Strategic Advisors LLC (0.19%).

Shares of BNR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BNR stock can currently be purchased for approximately $2.30.

Burning Rock Biotech (NASDAQ:BNR) has a market capitalization of $241.94 million and generates $81.66 million in revenue each year. The company earns $-140,820,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis.

The company employs 1,138 workers across the globe.

Burning Rock Biotech's mailing address is 601 BUILDING 3 STANDARD INDUSTRIAL UNIT2, GUANGZHOU F4, 510005. The official website for the company is www.brbiotech.com. The company can be reached via phone at 86-185-0164-1666.